ZL 82
Alternative Names: ZL-82Latest Information Update: 31 May 2024
At a glance
- Originator Chengdu Zenitar Biomedical Technology
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases; Rheumatoid arthritis; Ulcerative colitis
- Preclinical Atopic dermatitis; Vitiligo
Most Recent Events
- 01 Mar 2024 Chengdu Zenitar Biomedical Technology initiates enrolment in a phase I pharmacokinetic trial (In volunteers) in China (PO, Tablet) (NCT06432738)
- 16 Oct 2023 Phase-I clinical trials in Ulcerative colitis in China (PO) prior to October 2023 (Chengdu Zenitar Biomedical Technology pipeline, October 2023)
- 16 Oct 2023 Preclinical trials in Atopic dermatitis in China (PO) prior to October 2023 (Chengdu Zenitar Biomedical Technology pipeline, October 2023)